We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mutation Found Determines Nature of Host Response to MRSA Infection

By LabMedica International staff writers
Posted on 22 Sep 2019
Image: A scanning electron micrograph (SEM) of a human neutrophil ingesting MRSA (Photo courtesy of the U.S. National Institute of Allergy and Infectious Diseases).
Image: A scanning electron micrograph (SEM) of a human neutrophil ingesting MRSA (Photo courtesy of the U.S. National Institute of Allergy and Infectious Diseases).
A recent paper described the genetic factors that determine why some individuals develop chronic methicillin-resistant Staphylococcus aureus (MRSA) infections while others develop infections that resolve relatively quickly.

The severity and duration of MRSA infection varies widely between individuals. Host factors predisposing to persistent MRSA infection are poorly understood, although genetic association studies are beginning to identify potentially influential variants.

Investigators at Duke University (Durham, NC, USA) searched for such host factors by analyzing two sets of patients who had been closely matched by age, sex, health conditions, and other risk factors for MRSA bloodstream infections. Sixty-eight patients were included in the study; half with a persistent MRSA infection and half who had been able to clear the infection from their bloodstream. Whole-exome sequencing was used to pinpoint genomic differences between the two sets of patients.

Results revealed that a mutation located in the DNA of the DNMT3A region of chromosome 2p was expressed in about 62% of the patients who cleared their MRSA infection, while it was expressed in only 9% in those who had persistent infections.

In a further series of experiments, the investigators demonstrated that DNMT3A variants could alter host response to infection through increased methylation of key regulatory genes, which resulted in reduced interleukin-10 production and in turn, allowed for a more protective immune response that cleared infection.

"The increasing prevalence of antibiotic resistant staph infections has created an urgent need to better understand who is most susceptible to these difficult-to-treat S. aureus infections and why," said senior author Dr. Vance Fowler, professor of medicine, molecular genetics, and microbiology at Duke University. "Our study identifies a particular DNMT3A mutation that contributes to an increased ability to resolve MRSA infections. The mechanism for this appears to be increased methylation of gene regulatory regions, and reduced levels of the anti-inflammatory cytokine IL-10."

The MRSA paper was published in the September 16, 2019, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences.

Related Links:
Duke University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9

Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more